Disclosed herein are methods and compositions for the diagnosis and treatment of Vascular Associated Maculopathy, or a symptom thereof, in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of one or more symptoms associated with Vascular Associated Maculopathy Disclosed in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of severe maculopathy or last stage maculopathy in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of resolving aberrant choriocapillaris lobules in a subject.

The disclosure provides methods for treating estrogen receptor positive (ER.sup.+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER.sup.+ cancers.

Provided herein are genetic circuits and cell state classifiers for detecting the microRNA profile of a cell. The cell state classifiers of the present disclosure utilize phosphorylation state of a transcription factor to control classifier output. Kinases and phosphatase pairs that function in phosphorylating or dephosphorylating the transcription factor are integrated into the circuit, their expression tuned by the presence of microRNAs of interest (e.g., in a cell). The genetic circuits and cell state classifiers may be used in various applications (e.g., therapeutic or diagnostic applications).

The present invention relates to the filed of diagnostic and/or prognostic and/or subject stratification biomarker assays for the prognosis and/or diagnosis and/or therapy of high risk early psychosis subjects, wherein psychotic disorder may include schizophrenia, bipolar disorder (manic depression), epilepsy, mood disorder, age-related disorders, or cognitive impairment, or another psychotic disorder. The expression markers used are miR-137 and COX6A2. The present invention also relates to the use of mitochondria-targeted antioxidant in the treatment of subjects classified as high-risk early psychosis subjects and to a kit comprising means for determining said markers.

This invention relates generally to compositions and methods for identifying genes and gene networks that respond to, modulate, control or otherwise influence tumors and tissues, including cells and cell types of the tumors and tissues, and malignant, microenvironmental, or immunologic states of the tumor cells and tissues. The invention also relates to methods of diagnosing, prognosing and/or staging of tumors, tissues and cells, and provides compositions and methods of modulating expression of genes and gene networks of tumors, tissues and cells, as well as methods of identifying, designing and selecting appropriate treatment regimens.

Cell free nucleic acids from a test sample obtained from an individual are analyzed to identify possible fusion events. Cell free nucleic acids are sequenced and processed to generate fragments. Fragments are decomposed into kmers and the kmers are either analyzed de novo or compared to targeted nucleic acid sequences that are known to be associated with fusion gene pairs of interest. Thus, kmers that may have originated from a fusion event can be identified. These kmers are consolidated to generate gene ranges from various genes that match sequences in the fragment. A candidate fusion event can be called given the spanning of one or more gene ranges across the fragment.

The present invention relates to a method for diagnosing esthetic degradations of skin, in particular linked to pollution, in a subject, comprising a step (a) of determining, in a skin sample of the subject, the level of at least one marker chosen from the group constituted of (i) bacteria of the species Propionibacterim acnes, bacteria of the family Micrococcaceae, bacteria of the genus Brachybacterium, bacteria of the genus Brevibacterium, bacteria of the order Burkholderiales, bacteria of the genus Parococcus, bacteria of the family Rhodobacteraceae and bacteria of the genus Fusobacterium, and (ii) metabolites of these bacteria chosen from 3-hydroxy-3-methylglutarate, 3-methylglutarate/2-methylglutarate, 4-guanidinobutanoate, 4-imidazoleacetate, 5-oxoproline, aconitrate, adipate, alanine, alpha-cetoglutarate, arabonate/xylonate, azelate, beta-citrylglutamate, choline, cis-urocanate, citraconate/glutaconate, fructose, fumarate, gamma-glutamylalanine, gamma-glutamylglutamine, gamma-glutamylglycine, gamma-glutamylisoleucine, gamma-glutamylleucine, gamma-glutamylsérine, gamma-glutamylthréonine, gamma-glutamyltryptophane, gamma-glutamylvaline, glutarate, glycerate, glycerol-3-phosphate, glycine, isovalerylglycine, kynurenate, lactate, linoleoyl ethanolamide, malate, maleate, malonate, maltose, methionine sulfoxide, methylsuccinate, N-acetylalanine, N-acetylarginine, N-acetylaspartate, N-acetylglycine, N-acetylhistidine, N-acetylphenylalanine, N-acetylthréonine, N-acetylvaline, oleamide, ornithine, palmitamide, pimelate, proline, salicylate, sebacate, serine, suberate, succinate, undecanedioate and S-amino-omega caprolactam.

The present invention provides a target RNA detection method based on a dCas9/gRNA complex. A target RNA detection method according to the present invention can detect target RNA with the naked eye and without separate gene isolation and amplification steps, and, in particular, can rapidly and accurately detect target RNA through excellent target specificity and rapidity, and thus can exhibit excellent effects on the detection of various pathogens and/or viruses.

The present disclosure provides for and relates to the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurrence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth.

The present invention is directed to methods for detecting a plasma cell dyscrasia like myeloma or MGUS, methods for determining whether a plasma cell dyscrasiais stable or progressive, methods for determining a risk for disease relapse, and methods for determining a response by a subject having a plasma cell dyscrasia to a therapy.